{
    "title": "106_hr1039",
    "content": "SECTION 1. CREDIT FOR CLINICAL TESTING RESEARCH EXPENSES ATTRIBUTABLE TO CERTAIN QUALIFIED ACADEMIC INSTITUTIONS INCLUDING TEACHING HOSPITALS. This section introduces a new credit for medical innovation expenses under the Internal Revenue Code of 1986. The medical innovation credit under section 38 allows for a 20 percent credit on qualified medical innovation expenses paid to qualified academic institutions for clinical testing research activities. The medical innovation credit provides a 20 percent credit on qualified medical innovation expenses paid to qualified academic institutions for clinical testing research activities conducted before the approval of a product application under certain sections of the Federal Food, Drug, and Cosmetic Act. The term 'product' refers to any drug, biologic, or medical device under the Food, Drug, and Cosmetic Act. The term 'qualified academic institution' refers to educational institutions or teaching hospitals that are affiliated with an institution of higher education or publicly supported teaching hospitals owned by a 501(c)(3) organization. The curr_chunk describes a medical research organization affiliated with a 501(c)(3) organization or a teaching hospital meeting specific requirements. The curr_chunk discusses the exclusion of qualified medical innovation expenses funded by grants or contracts. It also defines the medical innovation base period amount as the average annual qualified medical innovation expenses. The curr_chunk specifies the average annual qualified medical innovation expenses for a specific taxable year period. Special rules include limitations on foreign testing and the application of certain rules from section 41. Taxpayers can elect to apply this section. The section applies to taxpayers who elect to have it apply for a taxable year. Any qualified medical innovation expense under this section cannot be used to determine the credit under section 41 or 45C for that year. This section does not apply to certain expenses. The section applies to taxpayers who elect to have it apply for a taxable year. Any qualified medical innovation expense under this section cannot be used to determine the credit under section 41 or 45C for that year. This section does not apply to any expense paid or incurred after the specified date in section 41(h)(1)(B). The medical innovation expenses credit is to be part of the general business credit. The new paragraph prohibits the carryback of the medical innovation credit before January 1, 1999. Additionally, a denial of double benefit is introduced for the credit related to increasing medical innovation expenses. The deduction for the unused portion of the medical innovation credit is addressed in section 196(c) of the Code, with specific rules and amendments outlined. The medical innovation expenses credit under section 41A(a) is amended by adding a new paragraph (5) after paragraph (4). A clerical amendment is made to the table of sections for subpart D of part IV of subchapter A of chapter 1 of the Code. The amendments made by this section apply to taxable years beginning after December 31, 1998."
}